Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes (review)

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3078186 22 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes (review)
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Soft tissue sarcomas (STS) are rare tumors; they do not even equate to 1% of all malignant tumor cases. One-fifth of all STS occur in the upper extremities, where epithelioid sarcoma, synovial sarcoma, clear cell sarcoma and malignant fibrohistiocytoma are the most frequent subtypes. Surgical resection is the cornerstone of treatment. However, accomplishment of optimal oncological and functional results of STS of the upper extremities may represent a challenge for hand surgeons, due to the complex anatomy. In several cases, preoperative therapies are needed to facilitate tumor resection and improve the oncological outcome. Oligometastatic disease may also be a challenging scenario as curative strategies can be applied. Radiotherapy and chemotherapy are commonly used for this purpose albeit with conflicting evidence. Novel drug combinations have also been approved in the metastatic setting, further improving the quality of life and survival of eligible patients. Thus, prior to any approach, every case should be individually discussed in sarcoma centers with specialized multidisciplinary tumor boards. The aim of the present review was to gather the multidisciplinary experiences of the available therapeutic strategies for STS of the upper extremities. © 2019, Spandidos Publications. All rights reserved.
Έτος δημοσίευσης:
2019
Συγγραφείς:
Duran-Moreno, J.
Kontogeorgakos, V.
Koumarianou, A.
Περιοδικό:
Oncology Letters
Εκδότης:
Spandidos Publications
Τόμος:
18
Αριθμός / τεύχος:
3
Σελίδες:
2179-2191
Λέξεις-κλειδιά:
anthracycline; antineoplastic agent; crizotinib; docetaxel; doxorubicin; epirubicin; gadolinium; gemcitabine; ifosfamide; olaratumab; pazopanib; pembrolizumab; sorafenib; sunitinib; tazemetostat; tinvatinib; trabectedin; unclassified drug; vasculotropin, adjuvant chemotherapy; brachytherapy; cancer chemotherapy; cancer radiotherapy; cancer recurrence; cancer surgery; clear cell sarcoma; computer assisted tomography; cytogenetics; diagnostic value; epithelioid sarcoma; external beam radiotherapy; fibrosarcoma; follow up; giant cell tumor of tendon sheath; histology; human; immunohistochemistry; intensity modulated radiation therapy; intraoperative radiotherapy; limb salvage; limb tumor; lipoma; metastasis resection; needle biopsy; nuclear magnetic resonance imaging; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); positron emission tomography; preoperative chemotherapy; pulmonary metastasectomy; quality of life; radiation dose; Review; sarcoma; soft tissue sarcoma; synovial sarcoma; treatment outcome; undifferentiated pleomorphic sarcoma; undifferentiated pleomorphic sarcoma; upper limb
Επίσημο URL (Εκδότης):
DOI:
10.3892/ol.2019.10575
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.